论文部分内容阅读
目的探讨缬沙坦联合美托洛尔治疗慢性心力衰竭的临床疗效。方法将我院2008年12月-2010年12月收治的96例慢性心力衰竭患者随机分为治疗组、对照组各48例,对照组给予抗心衰的常规治疗,治疗组在常规治疗的基础上加用缬沙坦和美托洛尔,两组疗程均为3个月,比较两组治疗前后的临床疗效及超声心动图心功能指标的变化。结果治疗组总有效率为93.8%,对照组的总有效率为70.8%,两组相比较有显著性差异(P<0.05);两组超声心动图的各项指标均较对照组有明显改善(P<0.05)。结论缬沙坦联合美托洛尔治疗慢性心力衰竭的疗效显著,明显改善患者预后,不良反应较少,值得临床上推广。
Objective To investigate the clinical efficacy of valsartan combined with metoprolol in the treatment of chronic heart failure. Methods 96 cases of chronic heart failure patients admitted in our hospital from December 2008 to December 2010 were randomly divided into treatment group and control group with 48 cases in each group. The control group was given routine anti-heart failure treatment. The treatment group was treated on the basis of routine treatment Add valsartan and metoprolol, the two groups were 3 months course of treatment, the clinical efficacy of both groups before and after treatment and echocardiography cardiac function changes. Results The total effective rate was 93.8% in the treatment group and 70.8% in the control group, with significant difference between the two groups (P <0.05). The indexes of echocardiography in both groups were significantly improved compared with the control group (P <0.05). Conclusion Valsartan combined with metoprolol in the treatment of chronic heart failure significant effect, significantly improve the prognosis of patients with fewer adverse reactions, it is worth clinical promotion.